Press Release
Details
AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020
AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020
Analyst and investor event to be webcast on
Analyst and investor event,
In addition to members of
Stephanie Cherqui , Ph.D., principal investigator of the Phase 1/2 clinical trial of AVR-RD-04 (CTNS-RD-04), an investigational gene therapy for cystinosis; associate professor of pediatrics atUniversity of California, San Diego , School of Medicine; and chair of theAmerican Society of Gene and Cell Therapy (ASGCT) Gene and Cell Therapy of Genetic and Metabolic Diseases Committee;Jeffrey A. Medin , Ph.D., principal investigator of theFabry Disease Clinical Research and Therapeutics (FACTs) clinical study of AVR-RD-01, AVROBIO’s investigational gene therapy for Fabry disease; vice chair of research innovation andMACC Fund professor, pediatrics (hematology/oncology) at theMedical College of Wisconsin ; andMark Thomas , M.D., lead investigator for the company-sponsored Phase 2 clinical trial of AVR-RD-01 (FAB-201) for Fabry disease; nephrologist at theDepartment of Nephrology ,Royal Perth Hospital ; and clinical professor at theUniversity of Western Australia Medical School .
A live webcast of the presentation and accompanying slides will be available at
Satellite symposium, “Lysosomal disorders: Lentiviral gene therapy and the promise of freedom for life,”
In addition to members of
Harry L. Malech , M.D., symposium chair and chief of the Genetic Immunotherapy Section, and deputy chief,Laboratory of Clinical Immunology and Microbiology in theNational Institute of Allergy and Infectious Diseases (NIAID),National Institutes of Health ; andAneal Khan , M.D., FACTs project investigator; and professor, Departments of Medical Genetics and Pediatrics at theUniversity of Calgary Cumming School of Medicine .
Scientific presentation: “Gb3 substrate in endothelial cells of renal peritubular capillaries was reduced in a previously untreated classic Fabry disease male patient treated with AVR-RD-01 investigational lentiviral gene therapy”
Birgitte Volck , M.D., Ph.D., president of research & development,AVROBIO , will present an update on theAVROBIO -sponsored Phase 2 trial of AVR-RD-01 in Fabry disease (FAB-201).- Poster presentation:
Wednesday, Feb. 12, 2020 , at4:30-6:30 p.m. ET . Contemporary Forum platform presentation:Thursday, Feb. 13, 2020 , at1:45 p.m. ET .
About
AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease.
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to”, “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our prospective product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, and anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005326/en/
Source:
Investor Contact:
Christopher F. Brinzey
Westwicke, an ICR Company
339-970-2843
chris.brinzey@westwicke.com
Media Contact:
Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com